Inveready in €3m round for Althia

Additional funding was provided by investment firms CECU Inversiones, SL and HSS, as well as Valencian family office Reiman Inversiones.

The fresh capital will support the activation of the firm's single dose radiotherapy treatment and the consolidation of the oncology sector.

Company
Founded in 2007 and based in Madrid, Althia is a biomedical firm that specialises in oncology. The company focuses on three areas: care in diagnosis and prognosis, translational research and SD-IGRT treatment.

Althia has laboratories in Barcelona and Granada and an office in Madrid.

People
Roger Piqué is a director at Inveready and worked on the deal, with a particular focus on legal due diligence. Inveready director Josep Echarri conducted commercial and management team due diligence as part of the deal.

Advisers
Equity (Inveready) – BDO Auditores, Agustin Checa (Financial due diligence).
Company – Ramón y Cajal Abogados, Inmaculada Castelló (Legal); Livingstone, Neil Collen (Corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Expansion
• Spain
• Inveready First Capital